Author Archives: Press Release
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
Strategic Expansion in Salt Lake City Headquarters Will Meet Stringent EU GMP Annex 1 Requirements
RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS
Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025
Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025
Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
Groundbreaking Preclinical Data Propel Clinical Milestone
Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
DOMESTIC STABLE ISOTOPE PROGRAM KEY TO STABILIZING SUPPLY CHAINS, ENABLING INNOVATION
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program
Seek Labs Unveils BioSeeker™
Bioseeker™ is the AI Discovery Engine Powering Seek Labs’ Mission to Outpace Disease with Faster, Smarter Global Health Solutions
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
